Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. - Qualls D; Noy A; Straus D; Matasar M; Moskowitz C; Seshan V; Dogan A; Salles G; Younes A; Zelenetz AD; Batlevi CL (Leukemia & lymphoma, 2023)